相关实验视频

Updated: Jun 22, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

铁皮胺酸盐作为一种基于病毒的疗法的新潜能剂

Akram Alwithenani^1,2,3, Rozanne Arulanandam¹, Boaz Wong^1,2

¹Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.

|June 27, 2024

概括

铁皮胺烟酸 (TPF) 通过增加病毒感染和癌细胞杀死来增强瘤性病毒疗法,优于二甲基烟酸 (DMF). 此外,TPF还提高了基因疗法载体的效率,显示出广泛的治疗潜力.

科学领域:

在瘤学瘤学.
病毒学病毒学
免疫学免疫学免疫学
基因治疗基因治疗

背景情况:

瘤性病毒疗法使用病毒向癌细胞,但面临诸如干扰素介导的细胞抵抗等挑战.
丁甲基烟酸 (DMF) 显示出抗癌性质,并增强瘤性病毒活性.
一种DMF模拟物,即特皮胺烟酸 (TPF) 正在针对牛皮进行测试,其在病毒治疗中的潜力尚未被探索.

研究的目的:

评估特皮胺烟酸 (TPF) 作为一种增强瘤性病毒疗法的药物.
为了比较TPF与二甲基烟酸 (DMF) 的疗效,改善病毒感染和癌细胞溶解.
研究TPF对干扰素 (IFN) 途径的影响及其在基因治疗中的潜力.

主要方法:

使用786-0癌细胞和其他携带VSVΔ51和HSV-1病毒的癌细胞系的体外研究.
在胰腺和卵巢瘤样本上的ex vivo分析.
评估TPF对IFN通路和基因疗法载体转导效率 (lentivirus,腺病毒5型,AAV2) 的影响.

主要成果:

TPF治疗增加了癌细胞对VSVΔ51感染和病毒复制的敏感性.
在测试的细胞系中,TPF在增强病毒感染和癌细胞杀死方面表现优于DMF.
在癌细胞中,特别是胰腺和卵巢瘤中,TPF可以选择性地促进瘤性病毒感染,而不会影响健康的组织.
TPF降低了IFN通路的调节,增加了癌细胞对病毒感染的脆弱性.
TPF提高了lentivirus,第5型腺病毒和AAV2载体的转导效率.

结论:

TPF是瘤解毒性病毒疗法的强效增强剂,显示出优于DMF的疗效.
由于TPF能够克服IFN介导的耐药性并增强病毒活性,使其成为一个有前途的治疗剂.
在改善基因疗法载体的传递和疗效方面,TPF显示出显著的潜力.
对于TPF在癌症治疗和基因治疗中的广泛治疗应用,需要进一步研究.

关键词:

在VSVΔ51中.癌症治疗方法癌症治疗方法基因治疗的基因疗法泰皮胺烟酸盐是什么病毒载体病毒载体

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...